|
RPG Life Sciences welcomed the India–EU Free Trade Agreement (FTA), noting that the proposed removal of the 11% tariff on pharmaceutical products is a laudable and forward-looking step.
The company said the move will significantly enhance the competitiveness of Indian pharma manufacturers in the European market, improve patient access to affordable, high-quality medicines, and strengthen long-term trade and innovation linkages between India and the EU.
Ashok Nair, managing director, RPG Life Sciences said, “The India–EU Free Trade Agreement, with removal of 11% tariff on pharmaceutical products, is a welcome development for the pharmaceutical sector and a decisive step in strengthening India’s position as a trusted global healthcare partner. It comes at a critical time, as global healthcare systems are actively looking to diversify and de-risk their supply chains, and India is uniquely positioned to address this need.
Besides significantly improving the cost competitiveness of Indian medicines in Europe, it opens opportunities for India to scale exports (something our government has also been actively promoting), expand product portfolios and deepen long-term partnerships with European healthcare systems, he added.
The agreement creates a strong incentive for Indian companies to invest further in quality, compliance and innovation aligned with global standards. Over time, this will support capacity expansion, employment generation and greater R&D investments within India, while ensuring that European patients benefit from reliable as well as cost-effective pharmaceutical solutions, said Nair.
|